Aditxt Commences Participant Enrollment for Mitomic Endometriosis Test Research
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 27 2025
0mins
Clinical Study Enrollment: Aditxt's subsidiary, Pearsanta, has started enrolling participants for a clinical study.
Mitomic Endometriosis Test: The study is focused on evaluating the Mitomic Endometriosis Test, a new blood-based diagnostic tool.
Purpose of the Test: This diagnostic aims to assist in the early detection of endometriosis.
Significance: Early detection of endometriosis can lead to better management and treatment options for affected individuals.
Analyst Views on ADTX
About ADTX
Aditxt, Inc. is a social innovation platform dedicated to accelerating promising health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
